Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bortezomib, and dexamethasone (RVd) during 18-week induction treatment followed by transplant resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy, regardless of maintenance therapy assi ...

Thank you very much Shirley. A few elements in your question. First point, I understood you were questioning on the partnership with Novavax and more specifically about the combination vaccines where we have, you understood very well, we really want to make sure that there is no compromise, neither on safety or efficacy, and we believe that a combination is only worth if you're at least as good or better than the best standalone products separately. That's exactly what we want to do with the combination vac ...

Online availability of Sanofi's half-year financial report for 2024 This document may be found on the company's corporate website: www.sanofi.com and downloaded from the "Investors" page, under the heading "Regulated Information in France". We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We pr ...

B.8.5. CAPITAL INCREASES | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------------------|----------------------------------------------------------|-------------------------------------------------|-------------------|---------------------------------------------------------------| | Range of exercise prices per share | | Number of options | Outstanding \nWeighted average \nresidual life (years) | Weighted average exercise price per \nshare (€) | Number o ...

35 Investor Relations Global gender balance 42% 41% Not reported in Q1 77% of leaders have completed the eLearning phase 33% of leaders have completed the full program FinancePipeline Finance appendices Pipeline appendices ESG appendices Collaborations Abbreviations | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------|-------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------- ...

XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophylaxis in previously treated children Results indicate highly effective bleed protection in children under 12 years of age with severe haemophilia A Published in NEJM, the pivotal XTEND-Kids study shows ALTUVOCT met primary and key secondary endpoints, which included occurrence of factor VIII inhibitors and annualised bleed rates (ABRs). Results revealed no development of factor VIII inhibitors and sustained protection from bleeding events wit ...

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A Paris, July 17, 2024 – Full results from the XTEND-Kids phase 3 study published in The New England Journal of Medicine (NEJM) highlights the efficacy, safety, and pharmacokinetic profile of ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein]. ALTUVIIIO (efanesoctocog alfa), a first-in-class, high-sustained factor VIII replacement therapy ...

Thomas Grenier As one of the largest providers of influenza vaccines to the United States with a range of options, Sanofi meets immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. This year's 2024/25 U.S. influenza season portfolio includes Fluzone High-Dose (Influenza Vaccine), Flublok (Influenza Vaccine) and Fluzone (Influenza Vaccine). IMPORTANT SAFETY INFORMATION FOR FLUZONE® (INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND ...

Key Takeaways Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases. KT-474 is being studied as a treatment for patients suffering from hidradenitis suppurativa and atopic dermatitis. It targets a key protein that plays a critical role in triggering the immune system response against invading pathogens. The two companies announced their partnership in 2020, with Kymera ...

Alones Creative Approval has come late in Q2'24 I do note that current revenue estimates for VRNA for 2024 average just $7M, albeit from just six analysts. That doesn't sound like a particularly high bar to clear in the first six months of the launch. Of course those estimates could be revised upwards, and pale in comparison to a 2029 sales estimate of $1.05B GlobalData. Nonetheless is doesn't seem like a rapid launch is predicted, especially when we consider Ohtuvayre is priced at $35.4K annually. The comp ...